CVM
Cel-Sci CorporationNYSEMKT
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Fri, Dec. 2, 7:36 AM
    • CEL-SCI (NYSEMKT:CVM) prices its public offering of 34,024,000 shares of common stock and accompanying warrants for a combined price of $0.125.
    • The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common at $0.20, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common at $0.18 and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common at $0.18.
    • The Series CC, DD and EE warrants are all immediately exercisable and have terms of five years, six months and nine months, respectively.
    • Gross proceeds should be ~$4.25M. Net proceeds will fund the development of Multikine, LEAPS and general corporate purposes.
    • CEL-SCI closed yesterday at $0.1793.
    • Shares are down 36% premarket.
    | Fri, Dec. 2, 7:36 AM | 5 Comments
  • Thu, Dec. 1, 4:07 PM
    • Nano cap CEL-SCI (NYSEMKT:CVM) slumps 29% after hours on average volume in response to its announcement of a public offering of stock and warrants. Prices, volumes and terms have yet to be announced.
    | Thu, Dec. 1, 4:07 PM | 3 Comments
  • Mon, Nov. 21, 10:52 AM
    | Mon, Nov. 21, 10:52 AM
  • Tue, Sep. 27, 7:22 AM
    • CEL-SCI Corporation (NYSEMKT:CVM) announces that it has received verbal notice from the FDA that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. The company expects to receive a formal letter within 30 days and will work diligently to address the matter. The specific reasons for the hold are not provided. The study currently has about 926 patients enrolled.
    • A full clinical hold means that no new patients can be recruited into the study and all dosing must cease. Patients currently enrolled can continue to be followed.
    • The primary endpoint of the study is overall survival over a three-year period. According to ClinicalTrials.gov, the estimated study completion date is December 2017.
    • CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.
    • Shares are down 13% premarket on light volume.
    | Tue, Sep. 27, 7:22 AM | 27 Comments
  • Tue, Sep. 6, 10:47 AM
    • CEL-SCI (CVM -6.1%) founder, President & Chairman Maximilian de Clara has resigned effective immediately due to health reasons. The company says it has no current plans to appoint a new President to succeed the 87-year old Mr. de Clara.
    | Tue, Sep. 6, 10:47 AM | 8 Comments
  • Tue, Aug. 23, 9:22 AM
    • Thinly traded nano cap CEL-SCI (NYSEMKT:CVM) eases 6% premarket on light volume in response to its announcement of an agreement with institutional investors for the direct placement of ~10M shares of common stock and five-year warrants to purchase up to ~5M shares of common at $0.55. Gross proceeds will be $5M. Closing date is August 26.
    • Yesterday's close was $0.5325.
    | Tue, Aug. 23, 9:22 AM | 11 Comments
  • Wed, Aug. 10, 8:07 AM
    • Cel-Sci (NYSEMKT:CVM): FQ3 EPS of -$0.03
    • Revenue of $0.13M (-67.5% Y/Y)
    • Press Release
    | Wed, Aug. 10, 8:07 AM
  • Wed, May 18, 9:16 AM
    • Nano cap CEL-SCI (NYSEMKT:CVM) is down 4% premarket on light volume in response to its announcement that it has entered into a definitive agreement with a single institutional investor to purchase 10M shares of common stock and warrants to purchase up to ~6.66M shares of stock, generating gross proceeds of $5M. The five-year warrants are exercisable at $0.55 per common share. Closing date is May 20.
    • Yesterday's close was $0.54.
    | Wed, May 18, 9:16 AM | 4 Comments
  • Tue, May 10, 5:11 PM
    • Cel-Sci (NYSEMKT:CVM): FQ2 EPS of -$0.07.
    | Tue, May 10, 5:11 PM
  • Tue, Feb. 9, 5:08 PM
    • Cel-Sci (NYSEMKT:CVM): FQ1 EPS of $0.02
    • Revenue of $0.02M
    | Tue, Feb. 9, 5:08 PM | 6 Comments
  • Dec. 11, 2015, 4:48 PM
    • Cel-Sci (NYSEMKT:CVM): FY15 EPS of -$0.42 vs. -$0.49 in FY14
    | Dec. 11, 2015, 4:48 PM | 2 Comments
  • Oct. 23, 2015, 8:56 AM
    • CEL-SCI (NYSEMKT:CVM) prices its public offering of stock and warrants at $0.67 per unit which will generate up to $12M in gross proceeds. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at $0.67 for a period of five years. Closing date is October 28.
    • Shares are down 9% premarket on increased volume.
    | Oct. 23, 2015, 8:56 AM | 5 Comments
  • Oct. 22, 2015, 5:26 PM
    • CEL-SCI (NYSEMKT:CVM) commences a public offering of common stock and warrants. Price, volume and terms have yet to be announced.
    | Oct. 22, 2015, 5:26 PM | 12 Comments
  • Aug. 7, 2015, 4:35 PM
    • Cel-Sci (NYSEMKT:CVM): FQ3 EPS of -$0.06 beats by $0.05.
    • Revenue of $0.39M (+3800.0% Y/Y) beats by $0.29M.
    | Aug. 7, 2015, 4:35 PM
  • May 8, 2015, 5:03 PM
    • Cel-Sci (NYSEMKT:CVM): FQ2 EPS of -$0.17 misses by $0.06.
    | May 8, 2015, 5:03 PM
  • May 6, 2015, 9:11 AM
    | May 6, 2015, 9:11 AM | 1 Comment